Genentech
FREE Daily Email Newsletter
FDA Warns of New Fake Batch of Cancer Drug Avastin
February 7, 2013 8:19 am | News | CommentsThe Food and Drug Administration is warning U.S. doctors about another counterfeit version of the cancer drug Avastin, the third case involving the best-selling Roche drug in the past year. The FDA said in an online post Tuesday that at least one batch of the drug distributed by a New York company does not contain the active ingredient in real Avastin.
FDA Approves New Use of Avastin Plus Chemotherapy for People with Metastatic Colorectal Cancer
January 24, 2013 2:58 am | News | CommentsGenentech, a member of the Roche Group has announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin ® (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).
FDA OKs Lucentis for Diabetes-Related Eye Disorder
August 13, 2012 4:01 am | News | CommentsWASHINGTON (AP) — The FDA on Friday approved Roche's injectable eye drug Lucentis for a new use in treating a diabetes-related condition that can cause blindness.
HHS Secretary Sebelius Announces Public-Private Partnerships to Fight HIV and AIDS
July 23, 2012 4:11 am | News | CommentsIn a speech at the opening session of the XIX International AIDS Conference (AIDS 2012), Health and Human Services (HHS) Secretary Kathleen Sebelius announced a series of innovative public-private partnerships in the fight against the HIV/AIDS epidemic.
ImmunoGen, Genentech Cancer Drug Meets Study Goal
April 2, 2012 4:15 am | News | CommentsNEW YORK (AP) — ImmunoGen Inc. and Genentech say that their experimental breast cancer treatment, which combines the drug Herceptin with a cell-killing agent, worked in a late-stage clinical trial.
Studies: Avastin May Fight Early Breast Cancers
January 26, 2012 3:09 am | by MARILYNN MARCHIONE,AP Chief Medical Writer | News | CommentsSurprising results from two new studies may reopen debate about the value of Avastin for breast cancer. The drug helped make tumors disappear in certain women with early-stage disease, researchers found.
Constellation Pharmaceuticals and Genentech Enter Broad Epigenetics Drug Discovery Collaboration
January 17, 2012 3:16 am | News | CommentsConstellation Pharmaceuticals, Inc., today announced that it has entered into a major strategic agreement with Genentech, a member of the Roche Group, to launch a broad collaboration based on the science of epigenetics and chromatin biology to discover and develop innovative treatments for cancer and other serious diseases.
Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics
January 9, 2012 3:23 am | News | CommentsXenon today announced a strategic alliance with Genentech, a member of the Roche Group, to discover and develop compounds and companion diagnostics for the potential treatment of pain.
Regeneron Announces Settlement of Patent Litigation with Genentech
January 3, 2012 3:27 am | News | CommentsRegeneron Pharmaceuticals, Inc. today announced that the company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEAT (aflibercept) Injection.
FDA Revokes Approval of Avastin for Breast Cancer
November 21, 2011 3:27 am | by LAURAN NEERGAARD,AP Medical Writer | News | CommentsWASHINGTON (AP) — The government delivered a blow to some desperate patients Friday as it ruled the blockbuster drug Avastin should no longer be used to treat advanced breast cancer.
Genentech Submits NDA for Rare Form of Advanced Skin Cancer
September 12, 2011 4:22 am | News | CommentsGenentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the FDA for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
Concentration Lowered in Tamiflu Medication
July 13, 2011 10:12 am | News | CommentsWhen flu season arrives this fall, a liquid form of Tamiflu—the most widely used anti-viral flu medication—will be available in a new, lower concentration to reduce the possibility of medication errors.
Judge Denies Roche and Genentech's Motions to Dismiss PDL BioPharma's Complaint
July 11, 2011 5:10 am | News | CommentsPDL BioPharma, Inc. has announced that on July 7, 2011, the Second Judicial District Court of Nevada ruled in favor of PDL on two motions to dismiss filed by Genentech and F. Hoffmann LaRoche, Ltd. (Roche) in PDL's lawsuit related to the 2003 settlement agreement with Genentech.
FDA Approves Rituxan
April 20, 2011 4:47 am | News | CommentsGenentech, a member of the Roche Group and Biogen Idec announced today that the FDA has approved Rituxan(R) (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).
FDA OKs Rituxan as Cancer Maintenance Treatment
January 31, 2011 3:49 am | News | CommentsNEW YORK (AP) — Biogen Idec Inc. and Genentech said Friday that the FDA has approved an additional use for blockbuster cancer drug Rituxan as a first-line maintenance treatment for patients with follicular lymphoma, a cancer of the blood.
Melanoma Drug Meets Study Goal
January 19, 2011 3:49 am | News | CommentsGenentech said its cancer drug RG7204 improved survival for people with melanoma, and slowed the progress of the disease.
Genentech Issues Avastin Response; Requests FDA Hearing
December 17, 2010 3:59 am | News | CommentsGenentech issues a complete response letter regarding the recent Avastin ruling and will request a hearing with the FDA.
Genentech's ECP-1 Bacterial Manufacturing Facility Named 2010 Facility of the Year Awards Overall Winner
November 8, 2010 5:07 am | Articles | CommentsISPE , has announced during the Keynote Session at its 2010 Annual Meeting in Orlando, Florida, USA, that Genentech’s ECP-1 Bacterial Manufacturing Facility is the overall winner of the 2010 Facility of the Year Awards (FOYA) program
FDA Extends Review of Genentech's Avastin
September 20, 2010 4:58 am | News | CommentsNEW YORK (AP) — Genentech, a unit of Swiss drug developer Roche, said Friday that the FDA extended a review of Avastin as an initial breast cancer treatment. The agency will take an additional 90 days to review the application, citing the need to review new information submitted by the company.
Genentech Provides Update on FDA Application for T-DM1
August 27, 2010 4:36 am | News | CommentsGenentech, a member of the Roche Group has announced that the FDA issued a Refuse to File letter for accelerated approval for the company's trastuzumab-DM1 (T-DM1) Biologics License Application (BLA).
Nebraska Man Sues Makers of Rituxan After Infection
August 12, 2010 4:35 am | by TIMBERLY ROSS, Associated Press Writer | News | CommentsOMAHA, Neb. (AP) — An Omaha man who contracted an infection that rendered him a quadriplegic after taking the immunosuppressant Rituxan says the drug's makers knew of the risk but didn't warn users right away
Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Genentech
August 3, 2010 4:51 am | News | CommentsSeattle Genetics has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech, Inc., a member of the Roche Group. Under the expanded agreement, Genentech will pay an upfront fee of $12 million for rights to utilize Seattle Genetics' ADC technology with additional antigens to be named by Genentech.
Faster Than A Speeding Bullet
July 28, 2010 11:51 am | by Mike Auerbach, Editor-In-Chief | Articles | CommentsWith a singular vision of purpose, and a drive to do "what’s best for the patient", Genentech’s ECP-1 project in Tuas, Singapore was completed 2 weeks ahead of a very aggressive 24 month schedule.
Biogen Second Quarter Profit Doubles Without Acorda Payment
July 20, 2010 5:01 am | News | CommentsWESTON, Mass. (AP) — Biogen Idec Inc. said today its profit more than doubled in the second quarter compared to a year ago, when it entered a partnership on a potential multiple sclerosis drug.
MRC Technology Enters Into an Exclusive License Agreement With Genentech
July 12, 2010 4:21 am | News | CommentsMRC Technology (UK) announced today that it has entered into an agreement with Genentech, Inc., a wholly owned member of the Roche Group for an exclusive license to a series of small molecule drug candidates for the potential treatment of neurological disease.
